Revance Therapeutics Inc (RVNC) Given Average Rating of “Buy” by Analysts

Shares of Revance Therapeutics Inc (NASDAQ:RVNC) have been given a consensus rating of “Buy” by the twelve brokerages that are presently covering the firm, MarketBeat reports. Four equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $46.63.

A number of research firms recently weighed in on RVNC. ValuEngine upgraded Revance Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday. Barclays began coverage on Revance Therapeutics in a research report on Monday, November 27th. They issued an “overweight” rating and a $31.00 price target for the company. Guggenheim reiterated a “neutral” rating and issued a $42.00 price target on shares of Revance Therapeutics in a research report on Thursday, January 4th. Cantor Fitzgerald set a $50.00 price target on Revance Therapeutics and gave the company a “buy” rating in a research report on Thursday, January 4th. Finally, Piper Jaffray Companies reiterated a “buy” rating and issued a $28.00 price target on shares of Revance Therapeutics in a research report on Friday, October 27th.

Revance Therapeutics (NASDAQ RVNC) opened at $31.50 on Monday. Revance Therapeutics has a 1 year low of $18.00 and a 1 year high of $37.45. The firm has a market capitalization of $1,126.88, a price-to-earnings ratio of -8.29 and a beta of 1.36.

Revance Therapeutics (NASDAQ:RVNC) last released its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.01) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.95) by ($0.06). Revance Therapeutics had a negative net margin of 37,161.00% and a negative return on equity of 67.85%. The company had revenue of $0.08 million during the quarter, compared to analyst estimates of $0.05 million. During the same quarter last year, the business earned ($0.64) EPS. The company’s revenue for the quarter was up .0% compared to the same quarter last year. equities research analysts expect that Revance Therapeutics will post -3.74 earnings per share for the current year.

In other Revance Therapeutics news, CEO L Daniel Browne sold 7,600 shares of the firm’s stock in a transaction dated Wednesday, November 22nd. The stock was sold at an average price of $24.94, for a total transaction of $189,544.00. Following the completion of the sale, the chief executive officer now directly owns 133,188 shares in the company, valued at approximately $3,321,708.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Mark J. Foley acquired 20,000 shares of the firm’s stock in a transaction on Tuesday, November 7th. The shares were acquired at an average price of $26.96 per share, with a total value of $539,200.00. Following the completion of the transaction, the director now directly owns 6,000 shares in the company, valued at approximately $161,760. The disclosure for this purchase can be found here. Company insiders own 18.86% of the company’s stock.

Several institutional investors have recently made changes to their positions in the company. Ameriprise Financial Inc. lifted its holdings in shares of Revance Therapeutics by 1.0% during the 2nd quarter. Ameriprise Financial Inc. now owns 22,904 shares of the biopharmaceutical company’s stock valued at $604,000 after buying an additional 225 shares during the last quarter. Legal & General Group Plc lifted its holdings in shares of Revance Therapeutics by 8.1% during the 2nd quarter. Legal & General Group Plc now owns 5,815 shares of the biopharmaceutical company’s stock valued at $152,000 after buying an additional 438 shares during the last quarter. The Manufacturers Life Insurance Company lifted its holdings in shares of Revance Therapeutics by 7.5% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 18,304 shares of the biopharmaceutical company’s stock valued at $483,000 after buying an additional 1,275 shares during the last quarter. Parametric Portfolio Associates LLC lifted its holdings in shares of Revance Therapeutics by 6.2% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 29,112 shares of the biopharmaceutical company’s stock valued at $769,000 after buying an additional 1,711 shares during the last quarter. Finally, Swiss National Bank lifted its holdings in shares of Revance Therapeutics by 7.9% during the 3rd quarter. Swiss National Bank now owns 35,450 shares of the biopharmaceutical company’s stock valued at $977,000 after buying an additional 2,600 shares during the last quarter. Institutional investors and hedge funds own 76.51% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this report on another website, it was illegally copied and reposted in violation of United States & international copyright and trademark law. The legal version of this report can be read at https://www.americanbankingnews.com/2018/02/05/revance-therapeutics-inc-rvnc-given-average-rating-of-buy-by-analysts.html.

About Revance Therapeutics

Revance Therapeutics, Inc is a clinical-stage biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical.

Analyst Recommendations for Revance Therapeutics (NASDAQ:RVNC)

Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply